Business
Natera Announces New Prospera™ Data at ATC Showcasing Innovation in Cell-Free DNA
New research on background cell-free DNA to refine transplant rejection risk SAN CARLOS, Calif., May 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a
About this update from Natera, Inc.
[{"type":"text","content":"New research on background cell-free DNA to refine transplant rejection risk\n\n\nSAN CARLOS, Calif., May 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its Prospera donor-derived cell-free DNA (dd-cfDNA) transplant assessment test at the 2020 American Transplant Congress (ATC), being held virtually from May 30-June 1, 2020.\n\n \n \n \n \n \n \n\n \nNatera's Medical Director of Organ Transplantation, Phil Gauthier, MD, MBA, will present a late breaking abstract on June 1, 2020 at 5:00 pm ET. The abstract is titled \"Factors influencing background cell-free DNA levels: implications for donor-derived cell-free DNA assessment in transplant patients.\" \nNatera will also host a sponsored satellite symposium titled \"Expanding our Expertise: Technological advancements in cfDNA to refine transplant rejection risk\" on June 1, 2020 at 12:25 pm ET, featuring presentations by several leading transplant physicians and nephrologists:\nIntroducing the PEDAL Study: Prospera Enhancement by Detecting Background cell-free DNA LevelsSpeakers:\nDaniel C. Brennan, MD, FACP; Professor of Medicine, Division of Nephrology, Johns Hopkins University School of Medicine and Medical Director, The Comprehensive Transplant Center Suphamai Bunnapradist, MD, MS; Transplant Nephrologist & Professor of Medicine, University of California Los Angeles (UCLA)Trifecta Study: Calibrating Natera dd-cfDNA assay against the Molecular Microscope® Diagnostic System (MMDx) Speaker:\nPhil Halloran, MD, PhD; Professor, Department of Medicine, University of Alberta, Edmonton, Canada and Director, Alberta Transplant Applied Genomics CentreProspera: Quantifying background cell-free DNA for enhanced performance Speaker:\nPhil Gauthier, MD, MBA; Medical Director of Organ Transplantation, Natera, Inc.\"Natera has performed over two million cfDNA tests to date and has more than 25 published papers on cfDNA,\" said Paul Billings, MD, PhD, Natera's Chief Medical Officer and SVP of Medical Affairs. \"We are excited to share our new research at this year's virtual ATC conference alongside several distinguished members of the transplant medical community.\"\nAbout the Prospera dd-cfDNA Organ Transplant TestThe Prospera test leverages Natera's core single-nucleotide (SNP)-based massi...